As of Nov 19, 2026, 1 of 1 active firms rate BFRI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BFRI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 1 analysts · -98% YoY
Next period, 1 analysts expect Biofrontera Inc to earn $-0.01 a share (range $-0.01 – $-0.01), versus $-0.41 a year earlier. Full-year consensus is $-0.18, growing to $0.43 the year after.
REVENUE · NEXT QUARTER
$11.0M
Range $11.0M – $11.0M · 1 analysts · +9% YoY
Revenue is expected to reach $11.0M (range $11.0M – $11.0M), +9.1% year-over-year. Full-year consensus is $46.4M, rising to $53.3M next year.
Top analysts covering Biofrontera Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BFRI.
#1
Bruce Jackson
Benchmark · Rank #487
Buy
$3.00+399.8% to target
Overall win rate
36%
+ Follow
#2
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$9.00+1399.5% to target
Overall win rate
28%
+ Follow
BFRI stock forecast FAQ
What is BFRI's average 12-month price target?+
The 1 active firms with a live target average $3.00 for Biofrontera Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low, as of Nov 19, 2026.
Is BFRI stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover BFRI?+
1 active firms have a recognized rating on Biofrontera Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BFRI?+
Among analysts who currently cover BFRI, Bruce Jackson of Benchmark has the strongest overall Quantellect track record (Rank #487). Their current call is Buy with a $3.00 target.
What is Biofrontera Inc's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 1 analysts. Full-year EPS is projected at $-0.18, rising to $0.43 the following year.
How much revenue is Biofrontera Inc expected to report next quarter?+
Consensus revenue is $11.0M (range $11.0M – $11.0M). Full-year revenue is projected at $46.4M, growing to $53.3M next year.
Have analysts been upgrading or downgrading BFRI lately?+
As of Nov 19, 2026, 1 of 1 active firms rate BFRI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BFRI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.